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Background: Patients with autosomal-recessively inherited Friedreich's ataxia (FA) may develop a hypertrophic
cardiomyopathy (CM), which potentially progresses towards a life-limiting problem. The typical features of
this CM and the sequence of progression are widely unknown.
Methods: Thirty-two consecutive patients with genetically conﬁrmed FA were included. All patients received
resting electrocardiogram (ECG), 24-hour Holter-ECG, echocardiography with speckle tracking imaging, cardiac
magnetic resonance imaging (cMRI) with late enhancement imaging (for replacement ﬁbrosis), and measure-
ment of high-sensitive troponin-T (hsTNT). In addition, morphological parameters were retrospectively com-
pared to data obtained ﬁve years before.
Results: Based on criteria comprising ejection fraction (b55%), left ventricular end-diastolic posterior wall thick-
ness (LVPWT ≥ 11 mm), ﬁbrosis on cMRI, hsTNT ≥ 14 ng/ml, or T-wave-inversion, in all but two patients a CM
could be detected (94%). Using these criteriawe propose the following staging: a)mild CM (n=5, 16%; T-wave-
inversion only); b) intermediate CM (n= 4, 13%; T-wave-inversion with hypertrophy but no ﬁbrosis); c) severe
CM (n=13, 41%; ﬁbrosis with raised hsTNT); and d) end-stage CM (n= 8; 25%; ejection-fraction b 55%). All pa-
tients with end-stage CM also showed ﬁbrosis on cMRI, T-wave-inversion, marked elevation in hsTNT, and a de-
crease in LVPWT during the last ﬁve years (from 10.7 ± 1.2 mm to 9.5 ± 1.3 mm, p = 0.025). In addition, 38%
suffered from supraventricular tachycardia on Holter-ECG.
Conclusions:A comprehensive cardiac assessmentwill unravel established CM in almost all patients with FAwith
electrocardiographic abnormalities as earliest signs. Advanced stages can be characterized by elevated hsTNT and
replacement ﬁbrosis leading to recession of hypertrophy, reduction of global myocardial function, and electrical
instability.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Friedreich's ataxia (FA) is a neurodegenerative disease, ﬁrst de-
scribed in 1863 by Nikolaus Friedreich [1], and is characterized by an
autosomal-recessive trait inducing spinocerebellar ataxia [2]. In addition
to the neurologic manifestation, cardiac and endocrinological organ in-
volvement is widely reported [3,4]. First symptoms often relate to theability and freedom from bias of
arinen-Hospital Unna, Obere
(F. Weidemann).
land Ltd. This is an open access articlspinocerebellar ataxia and occur during adolescence, but sometimes
even earlier [5]. The neurological syndrome is well characterized and
best described by the ICARS score (International Consensus Ataxia Rating
Scale) [6]. This score consists of 19 items addressing oculomotor function,
speech, kinetic functions, posture, and gait. The score has achieved high
acceptance in daily routine, provides prognostic information, and is help-
ful to stage the individual patient for neurological involvement.
In contrast, Friedreich cardiomyopathy (CM) is notwell characterized.
Only recently, a very basic algorithm to stage the cardiac involvementwas
proposed [7]. This staging was mainly based on echocardiographic mor-
phology and global left ventricular (LV) function. However, from other
types of hypertrophic CM it is known that electrical abnormalities, myo-
cardial ﬁbrosis and biomarkers for cardiac involvement are essential toe under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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netic resonance imaging (cMRI) with late enhancement (LE) imaging is
especially important since it allows non-invasive assessment of replace-
ment ﬁbrosis [9]. Although for FA patients no established causal therapy
is available best practice considerations suggest that they should be treat-
ed with general heart failure medications. Therefore, a comprehensive
cardiac workup is necessary to detect cardiac involvement, stage the CM
progression, and intensify therapy if needed.
We comprehensively characterized patients with FA using resting
electrocardiogram (ECG for repolarization abnormalities), 24-hour
Holter ECG (for arrhythmias), standard echocardiography (for mor-
phology), speckle tracking imaging (for regional deformation), cMRI
with late enhancement imaging (for ﬁbrosis), 24-hour blood pressure
measurement, and blood test for high sensitive troponin-T (hsTNT).
Using this information, we aimed to give a detailed description of vari-
ous disease stages in Friedreich CM and to describe the progression of
cardiac involvement over time.
2. Methods
2.1. Study population and protocol
Thirty-two consecutive patients with genetically proven FAwere in-
cluded in this study between June 2012 andOctober 2013. In all patients
the complete clinical work-up was done within two days including the
following investigations: Resting ECG for depolarization and repolariza-
tion abnormalities; 24-hour Holter ECG for supraventricular and ven-
tricular arrhythmias; standard echocardiography for morphology and
global systolic and diastolic function; cMRI with LE imaging for replace-
ment ﬁbrosis; 24-hour blood pressure measurement; and blood test for
hsTNT as a sensitive biomarker for myocardial damage. Morphological
data were compared to a retrospective echocardiographic visit acquired
ﬁve years before during the MICONOS trial (Mitochondrial protection
with Idebenone in Cardiac or Neurological Outcome Study) [7]. Accord-
ing to the Declaration of Helsinki written informed consent of all
patients or their guardians was obtained and the local ethical board ap-
proved the protocol.
2.2. Cardiac magnetic resonance imaging
CMRI was performed with intravenous injection of gadobenate
dimeglumine 0.1 mmol/kg (Multihance, Braco Diagnostics, Italy) on a
1.5-T scanner (Magnetom Symphony Quantum, Siemens Medical
Systems, Erlangen, Germany). LE images were acquired with inverse
recovery sequences (8 mm slice thickness, breath hold, ﬁeld of view
240 × 320 mm2, matrix size 165 × 256, repetition time 7.5 ms, echo
time 3.4ms, ﬂip angle 25°). Short axis views at the basal, mid and apical
segments, covering the entire ventricle, were used. Applying this LE
technique, every LV segment, using a standard 17-segment model,
was evaluated for the occurrence of myocardial replacement ﬁbrosis.
Standard cine breath-hold short axis images were used to determine
wall thickness, cardiac mass and ejection fraction. All cMRI data were
analyzed by experienced investigators blinded to echocardiographic
and clinical results.
2.3. Echocardiographic measurements
LV parasternal long-axis images with M-Mode echocardiography
(Vivid 7 [3.5 MHz], GE Vingmed Ultrasound AS, Horten, Norway) were
used for determination of end-diastolic and end-systolic dimensions
as well as LV septal (IVSD) and posterior wall (LVPWT) thickness and
left atrial diameter. LV ejection fraction (EF) by Simpson's formula was
calculated based on 2- and 4-chamber views. The stage of LV diastolic
functionwas diagnosed according to theAmerican Society of Echocardi-
ography (ASE) guidelines [10]. In addition, current and former IVSD andLVPWTwere compared to a retrospective echocardiographic evaluation
dated ﬁve years prior to study inclusion.
2.4. Electrocardiography
Twelve-lead surface ECGs were analyzed, with the reader blinded to
clinical information. Measurements were taken manually at a sweep of
25 mm/s. Standard criteria for ECG ﬁndings were applied and the fol-
lowing intervalsweremeasured: PR-, QRS-, QT-interval. A normal PR in-
terval was deﬁned as 120–200 ms. A normal QRS duration was deﬁned
as 70–119 ms. LV hypertrophy was assessed using the Sokolow–Lyon
index: SV1 + RV5 or RV6 is greater than 3.5 mV. ST-segment decline
was deﬁned as J-point decline in ≥1.5 mm in precordial leads and
≥1mm in limb leads. Inverted T wave was deﬁned as abnormal if it oc-
curred in V2 to V6, II, III or aVF. The occurrence of ventricular and supra-
ventricular arrhythmias was determined by 24-hour Holter-ECG. The
24-hourHolter-ECGwas checked for pauses (R–R intervals N 2.5 s), sup-
raventricular (SV) and ventricular extrabeats, and a decrease in night-
time heart rate (derived from a 15 min sequence between 2:00 AM
and 2:15 AM). Further, the mean night-time heart rate was calculated
to evaluate the ﬂuctuations as proposed [11].
2.5. Blood assays
Peripheral venous blood samples were obtained in the supine posi-
tion after a 15 min rest. Blood samples were immediately analyzed,
and hsTNT was measured by the Central Laboratory of the University
Hospital (Roche Diagnostics, 99th percentile 0.014 mg/l, i.e. 14 ng/l).
2.6. Ambulatory blood pressure measurement
24-Hour blood pressure measurement was performed using a stan-
dard digital oscillometric blood pressure device (Mobil-O-Graph NG
Version 20, I.E.M. GmbH, Germany). Blood pressure was measured
every 15 min throughout day and night cycles.
2.7. Deﬁnition of FA cardiomyopathy
The following parameters were used to deﬁne a CM: EF b 55% (for
global LV function), LVPWT ≥ 11 mm (for hypertrophy), LE positive
myocardium (for myocardial replacement ﬁbrosis), hsTNT ≥ 14 ng/ml
(for myocyte damage) and T-wave-inversion (for repolarization
abnormalities). If in a patient all these parameters were normal the
heart was deﬁned as no CM. A global LV function assessed by EF b 55%
was used to deﬁne end-stage CM based on the former studies [7].
In between these extreme variants presence of LV hypertrophy
(LVPWT ≥ 11 mm) was used to separate mild (=no hypertrophy)
and intermediate CM (=with hypertrophy). Further, presence of
myocardialﬁbrosis (LE positivemyocardium)deﬁned severe CM, because
replacement ﬁbrosis is an irreversible feature whereas “pure” LV hyper-
trophy may regress during treatment [9]. It has to be stated that both
the chosen parameters and the order for staging cannot be statistically
conﬁrmed.
2.8. Statistical analysis
Continuous data are presented as mean (standard deviation, SD) or
median (quartiles), and categorical variables as numbers (percentages).
Differences on continuous data among three groups were compared
using one-way analysis of variance (ANOVA) followed by either Tukey's
or Games–Howell multiple comparison post-hoc tests. Categorical data
were compared across groups using chi-square test. Differences in con-
tinuous data between baseline and follow-up were compared applying
paired Student's t test or paired sample Wilcoxon signed rank test.
Correlation between hsTNT and LE, stage of the disease, EF, as well as
LVPWT were studied with the Spearman's rank correlation (rs).
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performed using IBM SPSS, version 21 for Windows (SPSS).3. Results
Clinical data summary of the complete cohort is shown in Table 1.
The average age was 33 (13) years, and 69% of the FA patients were
male. Five patients (16%) presented with diabetes and most patients
showed advanced neurological involvement with an ICARS score of 59
(19). Overall, only 7 patients suffered from arterial hypertension and
blood pressure was normal at 24 hour blood pressure measurement in
21 patients. In general, hsTNT (median 14.0 ng/ml, quartiles 9.1–
21.3 ng/ml) was around the upper boundary of the normal reference
range (normal range b 14 ng/ml).
According to the deﬁnitions given above, in all but two patients (re-
spective age 68 and 50 years) a CM could be detected (94%). An end-
stage CM (i.e., EF b 55%)was found in 8 patients (=25% of the complete
cohort; mean age 27± 7 years). Next, the remaining 22 patients with a
CM were further categorized as described in Methods. An early CM (by
deﬁnition not hypertrophic and without replacement ﬁbrosis) was
found in 5 patients (16% of the complete cohort). Four patients (13%)
were found with an intermediate stage (being hypertrophic but no ﬁ-
brosis) and 13 patients (41%)were classiﬁed as a severe CM (presenting
ﬁbrosis but normal EF). The general ECG, Holter ECG, echocardiographic
and cMRI data for all CM subgroups are presented in Table 2 and Fig. 1. A
weak correlation between neurological involvement (ICARS score) and
the stage of the CM could be detected with the highest score in end-
stage CM patients (Table 2).3.1. Cardiac magnetic resonance imaging
Data for cMRI are shown in Table 2. All patients with an end-stage or
severe CMwere LE positive. None of the patients (n=11)with no, mild
or intermediate CM showed LE at cMRI. The distribution of the LE pat-
tern was very patchy making a quantitative measurement impossible.
Number of segments with LE was not signiﬁcantly different between
end-stage and severe CM (5.9 ± 3.7 vs. 4.5 ± 3.5, P = 0.41). Out of 21
patients with positive LE, 18 (85.7%) patients presented with midwall
enhancement, 1 (4.8%) with subendocardial enhancement, and 2
(9.5%) with transmural enhancement. There was no predominant re-
gion in the LV for the occurrence of LE. However, in general, LE positive
myocardium was more frequently seen in the basal LV segments. LV
mass index calculated by cMRI increased gradually with advancing CM
stages. Thiswasmainly triggered by an increase in LVdimension despite
a reduction of wall-thickness seen in echocardiography.Table 1
Clinical baseline characteristics of the Friedreich cohort (n = 32).
Gender (male/female) 22/10 (69%, 31%)
Age (years) 33 ± 13
Height (cm) 173 ± 11
Weight (kg) 70 ± 15
BMI (kg/m2) 23 ± 4
Heart rate (1/min) 77 ± 15
Systolic BP (mm Hg) 116 ± 9
Diastolic BP (mm Hg) 72 ± 7
Hypertension (yes/no) 7/25 (22%, 78%)
Hyperlipidemia (yes/no) 10/22 (31%, 69%)
Coronary artery disease (yes/no) 1/31 (3%, 97%)
Diabetes (yes/no) 5/27 (16%, 84%)
ICARS score 59 ± 19
hsTNT (ng/ml) 14.0 (9.1–21.3)
BMI, body mass index; BP, blood pressure; ICARS, International Consensus Ataxia Rat-
ing Scale; hsTNT, high sensitive troponin.3.2. Echocardiography
Data for LV morphology, dimension, systolic and diastolic function
are shown in Table 2. LVmass gradually increased and global longitudi-
nal strain decreased from normal towards the end-stage hearts. When
focusing on the change of morphology over a ﬁve year period (Table 3),
it became evident that patients in early CM stages developed wall thick-
ening over time. By contrast, LV walls thinned in patients with more ad-
vanced CM stages, and LV end-diastolic and end-systolic dimensions
were increased (Table 3). The individual change for end-diastolic LV
wall thickness in all available patients is shown in Fig. 2.
3.3. Electrocardiography
The dominant heart rhythm was sinus rhythm. Even all end-stage
patients with reduced EF were in sinus rhythm. At resting ECG, T-
wave inversionwas found in all, and ST elevation in 53% of CM patients.
T-wave inversion was therefore interpreted as the earliest sign for car-
diac involvement. No patients exhibited left bundle branch block, and
only one patient of the end-stage group showed a right bundle branch
block. QT durationwas in normal range in all groups. No relevant brady-
cardia was detected at Holter ECG. The main ﬁndings were supraven-
tricular arrhythmias, which were more prominent in the advanced CM
stages (prevalence 63%: 0% atrial ﬁbrillation, 0% atrial ﬂutter, 63% isolat-
ed SV, 38% SV couplets, and 38% SV runs). In contrast, ventricular ar-
rhythmias were not detected.
3.4. hsTNT as biomarker
In the two patients without CM hsTNT was within the normal range
(8.9 ± 0.6 ng/ml). In contrast, all patients with an end-stage CM had
markedly elevated hsTNT (median 23 ng/ml, range 15.1 to 121 ng/ml).
In general, hsTNT increased with advancing CM stage (Fig. 1). Fifteen
out of 21 patients (=71%) with myocardial ﬁbrosis had an elevated
hsTNT above the cut-off value of 14 ng/ml. None of the patients in the
early CM group had an elevated hsTNT. HsTNT correlated with positive
LE (rs = 0.68, p b 0.001) and with the stage of the disease (rs = 0.74,
p b 0.001) but not with LVPWT (rs =−0.04, p = 0.81). A weak correla-
tion with EF was found (rs =−0.39, p = 0.029).
4. Discussion
CMRIwith LE imaging and serological biomarkers provide important
information for the staging of cardiomyopathies, complementary to
standard diagnostic procedures like ECG and echocardiography. The
current study used established standard and advanced modalities to
systematically investigate different disease stages in patients with FA.
The main ﬁndings were: 1) almost all FA patients showed some degree
of cardiac involvement, with T-wave inversion as the earliest sign for a
CM; 2) CM progression frommild to advanced stages seems to be char-
acterized by an initial increase of wall thickness followed by a later de-
crease of wall thickness and LV dilatation; 3) cMRI with LE imaging is
useful to identify the more advanced stages of the CM and 4) an end-
stage CM, besides LV dysfunction, is characterized by elevated hsTNT
as a sign for chronic myocyte decay with subsequent myocardial re-
placement ﬁbrosis.
4.1. Staging the Friedreich cardiomyopathy
A systematic approach to CM in FA patients requires the comprehen-
sive assessment of many diverse aspects of the heart, including electri-
cal re- and depolarization, arrhythmias, morphological and tissue
changes, dimensions of the chambers and thewalls, diastolic and systol-
ic function, and – in addition – biomarkers for myocyte decay. Among
the patients reported here, only 6% showed no cardiac abnormality
and could be classiﬁed as CM free. Interestingly, these two patients
Table 2
Group characteristics.
No CM Early CM Intermediate CM Severe CM End-stage CM
n = 2 n = 5 n = 4 n = 13 n = 8
General data
Gender (male/female) 1/1 (50%, 50%) 4/1 (80%, 20%) 3/1 (75%, 25%) 7/6 (54%, 46%) 7/1 (87.5%, 12.5%)
Age (years) 59 ± 13 37 ± 16 32 ± 13 32 ± 11a 27 ± 7a
BMI (kg/m2) 25 ± 0.5 24 ± 3 25 ± 0.4 24 ± 4 20 ± 3
Clinical data
Heart rate (1/min) 70 ± 2 80 ± 12 76 ± 9 77 ± 17 77 ± 17
Systolic BP (mm Hg) 119 ± 4 119 ± 3 121 ± 8 113 ± 6 114 ± 13
Diastolic BP (mm Hg) 80 ± 6 73 ± 3 78 ± 11 70 ± 5 69 ± 7
Hypertension (yes/no) 1/1 (50%, 50%) 3/2 (60%, 40%) 1/3 (25%, 75%) 2/11 (15%, 85%) 0/8 (0%, 100%)
Hyperlipidemia (yes/no) 1/1 (50%, 50%) 1/4 (20%, 80%) 1/3 (25%, 75%) 7/6 (54%, 46%) 0/8 (0%, 100%)
Coronary artery disease
(yes/no)
0/2 (0%, 100%) 0/5 (0%, 100%) 0/4 (0%, 100%) 0/13 (0%, 100%) 1/7 (12.5%, 87.5%)
Diabetes (yes/no) 0/2 (0%, 100%) 0/5 (0%, 100%) 0/4 (0%, 100%) 2/11 (15%, 85%) 3/5 (37.5%, 62.5%)
ICARS score 61 ± 5 43 ± 17 45 ± 6 62 ± 19 70 ± 20
hsTNT (ng/ml) 8.9 (8.4–9.3) 7.2 (5.4–9.9) 10.8 (7.3–16.5) 14.8 (11.5–22.1) 23.0 (19.3–38.2)ab
Electrocardiography at rest
Sinus rhythm (yes/no) 2/0 (100%, 0%) 5/0 (100%, 0%) 4/0 (100%, 0%) 12/1 (92%, 8%) 8/0 (100%, 0%)
ST elevations (yes/no) 0/2 (0%, 100%) 1/4 (20%, 80%) 3/1 (75%, 25%) 7/6 (54%, 46%) 6/2 (75%, 25%)
T inversions (yes/no) 0/2 (0%, 100%) 5/0 (100%, 0%)a 4/0 (100%, 0%)a 13/0 (100%, 0%)a 8/0 (100%, 0%)a
LBBB (yes/no) 0/2 (0%, 100%) 0/5 (0%, 100%) 0/4 (0%, 100%) 0/13 (0%, 100%) 0/8 (0%, 100%)
RBBB (yes/no) 0/2 (0%, 100%) 0/5 (0%, 100%) 0/4 (0%, 100%) 0/13 (0%, 100%) 1/7 (87.5%, 12.5%)
P duration (ms) 100 ± 0 89 ± 6 96 ± 5 92 ± 11 79 ± 11ab
PQ duration (ms) 183 ± 24 147 ± 26 144 ± 26 134 ± 21 129 ± 19a
QT duration (ms) 414 ± 37 328 ± 70 373 ± 25 356 ± 44 381 ± 65
LV Sokolow index (mV) 3.1 ± 2.5 2.3 ± 1.0 3.9 ± 1.3 2.2 ± 0.9 2.0 ± 1.6
RV Sokolow index (mV) 0.7 ± 0.7 0.5 ± 0.4 0.4 ± 0.3 0.5 ± 0.4 0.9 ± 0.6
24-Hour ECG
Average HR 75 ± 0 80 ± 12 83 ± 9 79 ± 25 79 ± 12
Maximal HR 105 ± 28 133 ± 22 135 ± 19 139 ± 35 122 ± 40
Minimal HR 61 ± 1 58 ± 10 55 ± 7 53 ± 9 62 ± 18
Decreased nighttime HR
(yes/no)
1/1 (50%, 50%) 4/0 (100%, 0%) 4/0 (100%, 0%) 12/1 (92%, 8%) 8/0 (100%, 0%)
Long pauses (yes/no) 0/2 (0%, 100%) 0/5 (0%, 100%) 0/4 (0%, 100%) 1/12 (8%, 92%) 0/8 (0%, 100%)
SVE isolated/couplets/
triplets/runs
0/0/0/0 (0%, 0%, 0%, 0%) 2/1/0/0 (40%, 20%, 0%, 0%) 2/1/0/0 (50%, 25%, 0%, 0%) 5/8/2/1 (38.5%, 61.5%, 15%, 8%) 5/4/0/3 (62.5%, 50%, 0%, 37.5%)
VE isolated/couplets/
triplets/runs
0/0/0/0 (0%, 0%, 0%, 0%) 0/1/0/0 (0%, 20%, 0%, 0%) 3/0/0/0 (75%, 0%, 0%, 0%) 5/5/1/0 (38.5%, 38.5%, 8%, 0%) 6/4/0/0 (75%, 50%, 0%, 0%)
Echocardiography
LVEDD (mm) 44 ± 11 44 ± 3 45 ± 5 45 ± 5 46 ± 6
LVESD (mm) 31 ± 8 31 ± 3 31 ± 5 29 ± 4 36 ± 5b
FS (%) 35 ± 5 31 ± 4 36 ± 6 35 ± 5 27 ± 8
IVSD (mm) 9.5 ± 0.7 9.0 ± 0.7 10.0 ± 0.0 9.8 ± 1.0 9.8 ± 1.4
LVPWD (mm) 9.5 ± 0.7 9.0 ± 0.7 9.8 ± 0.5 9.7 ± 0.9 9.5 ± 1.3
LVMI (g/m2) 68 ± 11 69 ± 14 77 ± 13 82 ± 10 91 ± 18
EF (%) 67 ± 7 66 ± 8 64 ± 5 61 ± 7 48 ± 4abcd




0/2/0/0 5/0/0/0 2/2/0/0 10/3/0/0 3/2/1/2
Global longitudinal strain (%) −21 ± 4 −19 ± 3 −18 ± 2 −17 ± 3 −13 ± 2abcd
Cardiac magnetic resonance
imaging
Late enhancement (yes/no) 0/2 (0%, 100%) 0/5 (0%, 100%) 0/3 (0%, 100%) 13/0 (100%, 0%) 8/0 (100%, 0%)
Number of segments with
LE (n)
– – – 4.5 ± 3.5 5.9 ± 3.7
EF (%) 69 ± 0 70 ± 11 61 ± 9 61 ± 7a 47 ± 6ab
CO (l/min) 5.5 ± 0.3 6.6 ± 1.7 6.7 ± 0.4 5.3 ± 1.2 4.6 ± 1.9
LVMI (g/m2) 50 ± 8 65 ± 10 65 ± 17 66 ± 15 93 ± 21abd
BMI, body mass index; BP, blood pressure; CO, cardiac output; EF, ejection fraction; FS, fractional shortening; ICARS, International Consensus Ataxia Rating Scale; hsTNT, high sensitive
troponin; IVSD, interventricular septal wall thickness; LAD, end-systolic left atrial diameter; LBBB, left bundle branch block; LE, late enhancement; LV, left ventricular; LVEDD, left ventric-
ular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVMI, left ventricularmass indexed to body surface area; LVPWD, left ventricular posteriorwall thickness; RBBB,
right bundle branch block; RV, right ventricular; RWT, relative wall thickness; SVE, supraventricular ectopy; VE, ventricular ectopy.
a p b 0.05 vs. no CM.
b p b 0.05 vs. early CM.
c p b 0.05 vs. intermediate CM.
d p b 0.05 vs. severe CM.
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ﬁndings that a typical CMdevelops early in life [7].We thus hypothesize
that these patients are very unlikely to progress towards a life-threaten-
ing CM, although they carry a documented FA mutation.In contrast, in 25% of the total sample an end-stage CM could be doc-
umented and these patients were relatively young. Concordant with
former studies suggesting that advanced CM patients exhibit a compro-
mised EF [12] and in accordance with the recent large MICONOS trial
Fig. 1.Overview of the key cardiac parameters characterizing the cardiomyopathy (CM) stages. The evaluated parameterswere a) T-wave inversion in resting electrocardiography (yes/no) for
depolarization abnormality, b) increased end-diastolic posteriorwall thickness (LVPWT,≥11mm) for hypertrophy, c) late enhancement positivemyocardium(yes/no) for replacementﬁbrosis,
d) elevated high sensitive troponin (hsTNT,≥14 ng/ml) for myocyte damage, and e) decreased ejection fraction (EF, b55%) for global LV function.
54 F. Weidemann et al. / International Journal of Cardiology 194 (2015) 50–57that used this generally accepted cardiac parameter [7], we employed
the presence of a reduced EF as the principal criterion deﬁning the
end-stage of Friedreich CM. Of note, all investigated hearts showed
myocardial LE, hsTNT was markedly increased, LV was enlarged but
wall thickness not abnormally thickened. In this context, the progres-
sive changes of LV dimensions and wall thickness during the 5 year
follow-up by echocardiography is important. In particular, in end-
stage hearts the LV dilates but wall thickness decreases.
The staging algorithm in all other CM categories was based on
wall-thickness and ﬁbrosis. As myocardial replacement ﬁbrosis is
an irreversible feature, this pattern was used to deﬁne a severe CM.
Thus, the largest group of the cohort was categorized as severe CM
presenting with still normal global EF but with myocardial replace-
ment ﬁbrosis (Fig. 3). Despite normal EF, however, global longitudi-
nal strain was already signiﬁcantly reduced and hsTNT elevated. The
combination of reduced longitudinal strain and normal EF ﬁts to re-
cently published studies focusing on cardiac function in patients
with FA [13,14]. Thus, in this stage, ﬁbrosis had a major impact on re-
gional longitudinal function. In addition, most of these severe CM pa-
tients showed a decrease of wall thickness during natural disease
progression.
In contrast, the group of patients with intermediate CM presented
with the thickest LV walls. All but one patient developed an increase
of wall thickness during follow-up. There was no replacement ﬁbrosis
in these hearts and hsTNT was only slightly elevated.Table 3
Changes in left ventricular geometry and systolic function measured by echocardiography betw
No CM Early CM
n = 2 n = 5
LVEDD (mm) Baseline 41 ± 6 41 ± 2
Follow-up 44 ± 11 44 ± 3
LVESD (mm) Baseline 29 ± 12 25 ± 4
Follow-up 31 ± 8 31 ± 3
LVPWD (mm) Baseline 9.5 ± 0.7 8.8 ± 0.5
Follow-up 9.5 ± 0.7 9.0 ± 0.7
EF (%) Baseline 72 ± 9 70 ± 5
Follow-up 67 ± 7 66 ± 8
a p b 0.05 vs. baseline. For abbreviation, see Table 2.The group of patients with mild CM was relatively small. These
hearts were not yet hypertrophic according to both echocardiographic
and cMRI criteria. None showed signs of ﬁbrosis, and longitudinal func-
tion and hsTNT were still unaltered. The only detectable abnormality
was T-wave inversion in the ECG. Thus, whenever imaging and bio-
markers are normal in a Friedreich patient, one should search for T-
wave inversion in the ECG as the earliest sign of a potential CM.
4.2. Fibrosis in Friedreich cardiomyopathy
The LE pattern (=replacement ﬁbrosis) in patientswith FA seems dif-
ferent comparedwith other well-known patterns in hypertrophic cardio-
myopathies [15,16]. The LE in the affected hearts of our Friedreich cohort
was patchy and irregular, affecting different left ventricularwall segments
and showing a high variety regarding the degree of transmurality and
predominant location.
Replacement ﬁbrosis might not only indicate an advanced disease
stage from a morphological point of view, but may also play a major
role in patients' outcome with respect to symptoms and prognosis. It
has been reported in hypertrophic CM that the presence of LE increases
the susceptibility for arrhythmias [17], and a high amount of LE predict-
ed major adverse cardiac events in these patients [18,19]. It is still
unclear, why patients with cardiac involvement in FA experience pre-
mature death [20]. The development of ﬁbrosis might have a major
role in this, paving theway for arrhythmias and heart failure. Regardingeen baseline and 5-year follow-up.
Intermediate CM Severe CM End-stage CM
n = 4 n = 13 n = 8
44 ± 2 44 ± 8 42 ± 7
45 ± 5 45 ± 5 46 ± 6a
30 ± 5 28 ± 5 29 ± 6
31 ± 5 29 ± 4 36 ± 5a
9.3 ± 0.5 10.9 ± 1.9 10.7 ± 1.2
9.8 ± 0.5 9.7 ± 0.9a 9.5 ± 1.3a
65 ± 6 65 ± 6 62 ± 8
64 ± 5 61 ± 7 48 ± 4a










Fig. 3. A typical example of a 26 year-old female Friedreich's ataxia patient with severe cardiomyopathy. Left upper: T-wave inversion observed on resting electrocardiography. Right
upper: Patchy late enhancement positive regions in the left ventricle (LV) assessed by cardiac magnetic resonance imaging. Left lower: RetrospectiveM-mode echocardiography showing
LV hypertrophy with an end-diastolic wall thickness of 13 mm (ejection fraction = 66%). Right lower: M-mode echocardiography after 5 years of follow-up shows a decrease of end-di-
astolic wall thickness to 10 mm (ejection fraction = 60%). In addition, hsTNT was elevated (16.5 ng/ml) in this patient.
56 F. Weidemann et al. / International Journal of Cardiology 194 (2015) 50–57the latter, however, the end-stage patients of our cohort showed high
rates of supraventricular but not ventricular arrhythmias.
Interestingly, myocardial ﬁbrosis and the stage of the disease corre-
lated strongly with the level of hsTNT. Thus, hsTNT seems to be a suit-
able blood biomarker indicating the cumulative myocyte damage
leading to ﬁbrosis. This hypothesis is supported by the fact that all pa-
tients without ﬁbrosis had normal hsTNT levels. Friedman et al. recently
presented an interesting study, which investigated troponin I levels in a
cross-sectional cohort of rather asymptomatic Friedreich patients [21].
Forty-seven percent of all patients showed an elevation of troponin I,
with one third exhibiting levels compatible with acute myocardial in-
farction [21]. In our cohort, which included also advanced symptomatic
Friedreich patients, 50% of all patients showed increased levels of hsTNT
andmost of them (94%) were LE positive on cMRI. Thus, evidence is ac-
cumulating that hsTNT might not only be a marker of acute myocardial
injury but also of chronic remodeling processes linked to myocardial ﬁ-
brosis [22]. In this context the study by Koeppen et al. is very interesting
[23]. They showed in autopsy tissue that the main feature of the
Friedreich CM is chronic myocarditis with necrosis of heart ﬁbers and
endomysialﬁbrosis [23]. Thus, it can be speculated that these inﬂamma-
tory processes are responsible for the increased hsTNT.
4.3. Progression of cardiomyopathy
The current data implies that mild CM stages are characterized by
increased LVwall thickness only. Along disease progression complex re-
modeling processes lead to a decrease of wall thickness. Most probably,
this decrease of wall thickness is related to the development of ﬁbrosis.Concomitantly, the LV dilates and ﬁnally progresses towards impaired
global LV function. This theory is strongly supported by the longitudinal
echocardiographic follow-up over 5 years. In this context, the study by
Mariotti et al. is very interesting. They found a signiﬁcant reduction of
wall thickness during 12 months of treatment with Idebenone [24].
However, the patients included in their study exhibited an increased
wall thickness of N12 mm at baseline. Thus, the wall thinning over
time observed in these patients might rather indicate disease progres-
sion than a positive therapeutic response.
4.4. Clinical impact
The current study suggests that a Friedreich patient should be eval-
uated at least once by sophisticated imaging and electrocardiography
including blood biomarkers. A pure echocardiographic study will not
sufﬁce, as it will miss some advanced hearts with ﬁbrosis. For the detec-
tion of early cardiac involvement the classical ECG seems to be very
valuable. In contrast, in advanced stages, a sophisticated cMRI might
be necessary.
Recently, a gene therapy for the Friedreich heart was established in a
mousemodel [25]. If this concept holds promise andwill be transferred
into clinical application, it will become necessary to search for ﬁbrosis in
advance because this morphological feature is considered irreversible.
5. Limitations
For the evaluation of CM progression only echocardiographic data
were used, as during the retrospective MICONOS trial no LE imaging
57F. Weidemann et al. / International Journal of Cardiology 194 (2015) 50–57and hsTNT was acquired. Thus, progression of myocardial ﬁbrosis and
ECG abnormalities could not be quantiﬁed. Becausemyocardial biopsies
were not sampled for ethical reasons we were unable to determine the
histological pathology underlying the observed morphological and
functional changes.
In addition, the current study does not provide any long-term out-
come to prove that the classiﬁcation reported may stratify risk among
FA patients.
The inclusion of FA patients in the current study might be limited by
a selection bias. Thus, one can speculate that patients with less ad-
vanced disease may have tended to agree to be studied in the present
investigation, while other more diseased patients more likely refused.
6. Conclusions
Almost all patientswith FA exhibit somedegree of CM if a systematic
assessment of the Friedreich heart is employed. Myocardial ﬁbrosis is
frequently found and pivotal for the appropriate staging the CM. Over
time, profound alterations in cardiac morphology and function can be
observed and quantiﬁed, now offering the possibility to evaluate poten-
tial treatment effects with greater conﬁdence and precision.
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